XML 17 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Revenue:      
Core companion animal health $ 105,191 $ 107,398 $ 84,249
Other vaccines, pharmaceuticals and products 24,150 22,685 20,348
Total revenue, net 129,341 130,083 104,597
Cost of revenue 71,080 76,191 60,384
Gross profit 58,261 53,892 44,213
Operating expenses:      
Selling and marketing 23,225 22,092 21,339
Research and development 2,004 2,147 1,658
General and administrative 14,813 13,120 12,659
Total operating expenses 40,042 37,359 35,656
Operating income 18,219 16,533 8,557
Interest and other (income) expense, net (150) 29 130
Income before income taxes 18,369 16,504 8,427
Income tax expense:      
Current income tax expense 49 407 1,581
Deferred income tax expense 8,864 3,932 1,327
Total income tax expense 8,913 4,339 2,908
Net income 9,456 12,165 5,519
Net (loss) income attributable to non-controlling interest (497) 1,657 280
Net income attributable to Heska Corporation $ 9,953 $ 10,508 $ 5,239
Earnings Per Share [Abstract]      
Basic earnings per share attributable to Heska Corporation (in dollars per share) $ 1.42 $ 1.55 $ 0.80
Diluted earnings per share attributable to Heska Corporation (in dollars per share) $ 1.30 $ 1.43 $ 0.74
Weighted average outstanding shares used to compute basic earnings per share attributable to Heska Corporation 7,026 6,783 6,509
Weighted average outstanding shares used to compute diluted earnings per share attributable to Heska Corporation 7,642 7,361 7,074